Open Access

Plasma sICAM-1 correlates with tumor volume before primary radiochemotherapy of head and neck squamous cell carcinoma patients

Kerstin Clasen

Kerstin Clasen

Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls UniversityTuebingen, Germany
Search for this author on
Sciendo|Google Scholar
Clasen, Kerstin
, 
Stefan Welz

Stefan Welz

Department of Radiation Oncology, Marienhospital StuttgartStuttgart, Germany
Search for this author on
Sciendo|Google Scholar
Welz, Stefan
, 
Heidrun Faltin

Heidrun Faltin

Section for Experimental Radiation Oncology, Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls UniversityTuebingen, Germany
Search for this author on
Sciendo|Google Scholar
Faltin, Heidrun
, 
Daniel Zips

Daniel Zips

  • Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls UniversityTuebingen, Germany
  • German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) partner site TuebingenTuebingen, Germany
Search for this author on
Sciendo|Google Scholar
Zips, Daniel
 and 
Franziska Eckert

Franziska Eckert

  • Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls UniversityTuebingen, Germany
  • Section for Experimental Radiation Oncology, Department of Radiation Oncology, Medical Faculty and University Hospital, Eberhard Karls UniversityTuebingen, Germany
  • German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) partner site TuebingenTuebingen, Germany
  • Department of Radiation Oncology, Medical University Vienna, AKH, Comprehensive Cancer CenterVienna, Austria
Search for this author on
Sciendo|Google Scholar
Eckert, Franziska
  
Dec 13, 2022
Plasma sICAM-1 correlates with tumor volume before primary radiochemotherapy of head and neck squamous cell carcinoma patients's Cover Image
About this article
Previous Article
Next Article
Cite
Download Cover
Article Category: Research Article
Published Online: Dec 13, 2022
Page range: 501 - 507
Received: Aug 31, 2022
Accepted: Sep 29, 2022
DOI: https://doi.org/10.2478/raon-2022-0043
Keywords
© 2022 Kerstin Clasen, Stefan Welz, Heidrun Faltin, Daniel Zips, Franziska Eckert, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

Figure 1

Plasma of three patients before and at end of radiochemotherapy for head and neck squamous cell carcinoma were analyzed with a human cytokine array. Of the tested cytokines, only six were present in detectable concentrations (Ccl5, Complement Component, SDF1, sICAM-1, MIF and SerpinE1). sICAM-1 was the only cytokine with a significant difference between the tested time points decreasing after treatment. sICAM-1 abundance showed moderate and strong correlations with SDF1 and SerpinE1, respectively.
Plasma of three patients before and at end of radiochemotherapy for head and neck squamous cell carcinoma were analyzed with a human cytokine array. Of the tested cytokines, only six were present in detectable concentrations (Ccl5, Complement Component, SDF1, sICAM-1, MIF and SerpinE1). sICAM-1 was the only cytokine with a significant difference between the tested time points decreasing after treatment. sICAM-1 abundance showed moderate and strong correlations with SDF1 and SerpinE1, respectively.

Figure 2

Blood samples were taken weekly during radiochemotherapy and at every follow-up visit of the patients. In total, 86 samples were evaluated at the different time points as shown in the table for every single patient included in the study (A). sICAM-1 concentrations measured by ELISA in plasma samples of 11 patients differed significantly between patients. Over the course of treatment and compared intraindividually before and after treatment sICAM-1 concentrations did not show significant changes (B). Initial sICAM-1 concentrations showed a moderate negative correlation with relative sICAM-1 levels at the end of treatment (C).
Blood samples were taken weekly during radiochemotherapy and at every follow-up visit of the patients. In total, 86 samples were evaluated at the different time points as shown in the table for every single patient included in the study (A). sICAM-1 concentrations measured by ELISA in plasma samples of 11 patients differed significantly between patients. Over the course of treatment and compared intraindividually before and after treatment sICAM-1 concentrations did not show significant changes (B). Initial sICAM-1 concentrations showed a moderate negative correlation with relative sICAM-1 levels at the end of treatment (C).

Figure 3

Kaplan Meier analysis of disease-free survival stratified by median initial sICAM-1 concentration showed that the two patients with early recurrence in the first year after treatment were in the group with high sICAM-1 levels. Disease-free survival in the small patient cohort did not differ significantly for high and low sICAM-1 concentrations.
Kaplan Meier analysis of disease-free survival stratified by median initial sICAM-1 concentration showed that the two patients with early recurrence in the first year after treatment were in the group with high sICAM-1 levels. Disease-free survival in the small patient cohort did not differ significantly for high and low sICAM-1 concentrations.

Figure 4

sICAM-1 levels at time points with manifest infections showed a tendency to higher concentrations compared to all other time points, however, without statistical significance (A). No difference in sICAM-1 concentrations was observed comparing time points with different documented Radiation Therapy Oncology Group (RTOG) toxicity grades (B).
sICAM-1 levels at time points with manifest infections showed a tendency to higher concentrations compared to all other time points, however, without statistical significance (A). No difference in sICAM-1 concentrations was observed comparing time points with different documented Radiation Therapy Oncology Group (RTOG) toxicity grades (B).

Figure 5

After exclusion of one patient with a large, mostly necrotic lymph node metastasis, initial pretherapeutic sICAM-1 levels showed moderate positive correlations with primary tumor volumes (A) and volumes of lymph node metastases (B) contoured for radiotherapy planning and a strong correlation with the sum of these volumes (gross tumor volume [GTV] hull, (C)) indicating the total tumor burden of the patient at the time point of initiation of radiotherapy.
After exclusion of one patient with a large, mostly necrotic lymph node metastasis, initial pretherapeutic sICAM-1 levels showed moderate positive correlations with primary tumor volumes (A) and volumes of lymph node metastases (B) contoured for radiotherapy planning and a strong correlation with the sum of these volumes (gross tumor volume [GTV] hull, (C)) indicating the total tumor burden of the patient at the time point of initiation of radiotherapy.
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed